A PD-1T signature as clinical applicable biomarker in NSCLC 149 4 with comparable predictive performance. This could provide a straightforward FFPEbased approach that allows for easy implementation in a routine diagnostic clinical setting. Moreover, the strategy used has the potential to bring other expression-level based biomarkers to routine clinical diagnostics where these can support shared decision making for therapeutic strategies.
RkJQdWJsaXNoZXIy MTk4NDMw